(131)I-MIBG, (90)Y-DOTATATE or (177)Lu-DOTATATE in the management of patients with metastatic/progressive phaeochromocytomas and paragangliomas.
Phase of Trial: Phase IV
Latest Information Update: 28 Aug 2017
At a glance
- Drugs 90Y DOTATATE (Primary) ; Iobenguane (Primary) ; Lutetium-(177Lu)-oxodotreotide (Primary)
- Indications Paraganglioma; Phaeochromocytoma
- Focus Adverse reactions; Therapeutic Use
- 28 Aug 2017 New trial record